Impulse control disorders in Parkinson’s disease: An overview from neurobiology to treatment

Journal of Neurology

Volumn 262, Issue 1, 2015, Pages 7-20

  Maréchal, Emke ^a,b   Denoiseux, Benjamin ^b   Thys, Ellen ^b   Crosiers, David ^a,b,c,d   Pickut, Barbara ^a,e   Cras, Patrick ^a,b,c  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e Hauenstein Neuroscience Center   (United States)

Author keywords

Caregiver; Impulse control disorders; Parkinson s

Indexed keywords

AMANTADINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

BEHAVIOR CHANGE; BRADYKINESIA; BRAIN DEPTH STIMULATION; CAREGIVER BURDEN; COGNITION; DOPAMINE RELEASE; DRUG DOSE REDUCTION; GENETIC SUSCEPTIBILITY; HUMAN; IMPULSE CONTROL DISORDER; NEUROBIOLOGY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RIGIDITY; RISK FACTOR; TREMOR; WITHDRAWAL SYNDROME; COMPLICATION; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; GENETICS;

DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; HUMANS; PARKINSON DISEASE;

EID: 84926675462     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7361-4     Document Type: Review

References (143)

1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535
2. Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64(8): 1089–1096
3. Voon V et al (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66(11):1750–1752
4. Burkhard PR et al. (2008) Impulse control disorders and Parkinson’s disease. Rev Med Suisse 4(156): 1145–1148, 1150.
5. Ceravolo R et al (2009) Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 15(Suppl 4):S111–S115
6. Pontone G et al (2006) Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67(7):1258–1261
7. Bonfanti AB, Gatto EM (2010) Kleptomania, an unusual impulsive control disorder in Parkinson’s disease? Parkinsonism Relat Disord 16(5):358–359
8. Avanzi M et al (2008) The thrill of reckless driving in patients with Parkinson’s disease: an additional behavioural phenomenon in dopamine dysregulation syndrome? Parkinsonism Relat Disord 14(3):257–258
9. Bienfait KL et al (2010) Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. J Clin Neurosci 17(4):539–540
10. Avanzi M et al (2006) Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 21(12):2068–2072
11. Weintraub D et al (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63(7):969–973
12. Lee JY et al (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord 24(12):1803–1810
13. Lee JY et al (2010) Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 16(3):202–207
14. Weintraub D et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589–595
15. Voon V et al (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67(7):1254–1257
16. Singh A et al (2007) Risk factors for pathologic gambling and other compulsions among Parkinson’s disease patients taking dopamine agonists. J Clin Neurosci 14(12):1178–1181
17. Fan W et al (2009) Impulse control disorders in Parkinson’s disease in a Chinese population. Neurosci Lett 465(1):6–9
18. Weintraub D et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord 24(10):1461–1467
19. Shaffer HJ, Hall MN, Bilt JV (1999) Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 89(9):1369–1376
20. Petry NM, Stinson FS, Grant BF (2005) Comorbidity of DSMIV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 66(5):564–574
21. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision (DSM-IV-TR). Amercian Psychiatric Association, Washington, DC
22. Fiorillo CD, Tobler PN, Schultz W (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299(5614):1898–1902
23. Lim SY et al (2009) Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease. J Clin Neurosci 16(9):1148–1152
24. Gescheidt T, Bares M (2011) Impulse control disorders in patients with Parkinson’s disease. Acta Neurol Belg 111(1):3–9
25. Jimenez-Jimenez FJ et al (2002) Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 36(7–8):1178–1179
26. McElroy SL et al (1994) Compulsive buying: a report of 20 cases. J Clin Psychiatry 55(6):242–248
27. Molina JA et al (2000) Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 15(5):869–872
28. Chen H et al (2003) Weight loss in Parkinson’s disease. Ann Neurol 53(5):676–679
29. Ondo WG, Lai D (2008) Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 14(1):28–32
30. Giovannoni G et al (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68(4):423–428
31. Wolters E, van der Werf YD, van den Heuvel OA (2008) Parkinson’s disease-related disorders in the impulsive-compulsive spectrum. J Neurol 255(Suppl 5):48–56
32. Storch A et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800–809
33. Pezzella FR et al (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Mov Disord 20(1):77–81
34. Cilia R et al (2014) Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 85(3):311–318
35. Evans AH et al (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19(4):397–405
36. Silveira-Moriyama L et al (2006) Punding and dyskinesias. Mov Disord 21(12):2214–2217
37. Isaias IU et al (2008) The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord 23(3):411–415
38. Voon V et al (2007) Factors associated with dopaminergic drugrelated pathological gambling in Parkinson disease. Arch Neurol 64(2):212–216
39. Gallagher DA et al (2007) Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22(12): 1757–1763
40. Vitale C et al (2011) Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov Disord 26(5):830–836
41. Grosset KA et al (2006) Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21(12):2206–2208
42. Antonini A et al (2011) Impulsivity and compulsivity in drug-naive patients with Parkinson’s disease. Mov Disord 26(3):464–468
43. Weintraub D et al (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80(2):176–180
44. Driver-Dunckley ED et al (2007) Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30(5):249–255
45. Holman AJ (2009) Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 25(3):425–431
46. Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97
47. Weintraub D (2008) Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 64(Suppl 2):S93–S100
48. Leroi I et al (2012) Apathy and impulse control disorders in Parkinson’s disease: a direct comparison. Parkinsonism Relat Disord 18(2):198–203
49. Santangelo G et al (2009) Cognitive dysfunctions and pathological gambling in patients with Parkinson’s disease. Mov Disord 24(6):899–905
50. Blum K et al (1995) Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5(3):121–141
51. Comings DE et al (1999) Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 88(4):358–368
52. de Castro IP (1997) Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 7(5):345–348
53. Lee JY et al (2012) Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson’s disease. Parkinsonism Relat Disord 18(1):76–78
54. Lundstrom K, Turpin MP (1996) Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225(3):1068–1072
55. Brewer JA, Potenza MN (2008) The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75(1):63–75
56. McFarland K, Lapish CC, Kalivas PW (2003) Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 23(8):3531–3537
57. Vallelunga A et al (2012) Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord 18(4):397–399
58. Nuytemans K et al (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30(7):1054–1061
59. van Eimeren T et al (2010) Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 75(19):1711–1716
60. Steeves TD et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132(Pt 5):1376–1385
61. Guthrie M, Myers CE, Gluck MA (2009) A neurocomputational model of tonic and phasic dopamine in action selection: a comparison with cognitive deficits in Parkinson’s disease. Behav Brain Res 200(1):48–59
62. Grace AA (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95(Suppl 2):S119–S128
63. Cilia R et al (2008) Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65(12):1604–1611
64. Joutsa J et al (2012) Increased medial orbitofrontal [18F] fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord 27(6):778–782
65. Volkow ND, Fowler JS, Wang GJ (2003) The addicted human brain: insights from imaging studies. J Clin Invest 111(10):1444–1451
66. Martin-Soelch C et al (2003) Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers. Eur J Neurosci 18(3):680–688
67. Evans AH et al (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59(5):852–858
68. Reuter J et al (2005) Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8(2):147–148
69. Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 61(3):422–423
70. Dodd ML et al (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62(9):1377–1381
71. Cools R et al (2001) Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex 11(12):1136–1143
72. Djamshidian A et al (2012) Decision making, impulsivity, and addictions: do Parkinson’s disease patients jump to conclusions? Mov Disord 27(9):1137–1145
73. Voon V et al (2011) Dopamine agonists and risk: impulse control disorders in Parkinson’s disease. Brain 134(Pt 5):1438–1446
74. Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67(1):58–63
75. Pondal M et al (2013) Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 84(2):130–135
76. Cunnington AL, White L, Hood K (2012) Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord 18(9):1051–1052
77. Papay K et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17(3):153–155
78. Weintraub D et al (2012) Questionnaire for impulsive-compulsive disorders in Parkinson’s Disease-Rating Scale. Mov Disord 27(2):242–247
79. Visser M et al (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22(15):2221–2228
80. Christenson GA et al (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55(1):5–11
81. Lesieur HR, Blume SB (1987) The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 144(9):1184–1188
82. Bastiaens J et al (2013) Prospective cohort study of impulse control disorders in Parkinson’s disease. Mov Disord 28(3):327–333
83. Mamikonyan E et al (2008) Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 23(1):75–80
84. Sohtaoglu M et al (2010) Long term follow-up of Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord 16(5):334–337
85. Ardouin C et al (2006) Pathological gambling in Parkinson’s disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21(11):1941–1946
86. Bandini F et al (2007) Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson’s disease. Parkinsonism Relat Disord 13(6):369–371
87. Eusebio A et al (2013) Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(8):868–874
88. Smeding HM et al (2007) Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 78(5):517–519
89. Moum SJ et al (2012) Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 7(1):e29768
90. Kim YE et al (2013) Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson’s disease. J Clin Neurosci 20(7):964–969
91. Lhommee E et al (2012) Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain 135(Pt 5):1463–1477
92. Krack P et al (1998) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson’s disease. Brain 121(Pt 3):451–457
93. Rogers RD et al (2011) Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson’s disease. Exp Neurol 231(1):181–189
94. Thomas A et al (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404
95. Lee JY, Kim HJ, Jeon BS (2011) Is pathological gambling in Parkinson’s disease reduced by amantadine? Ann Neurol 69(1):213–214 (author reply 214–215)
96. Walsh RA, Lang AE (2012) Multiple impulse control disorders developing in Parkinson’s disease after initiation of amantadine. Mov Disord 27(2):326
97. Weintraub D et al (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963–968
98. Grant JE, Potenza MN (2004) Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 16(1):27–34
99. Fong T et al (2008) A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 89(3):298–303
100. Seedat S et al (2000) Pathological gambling behaviour: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety 11(4):185–186
101. Bostwick JM et al (2009) Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 84(4):310–316
102. Rotondo A et al (2010) Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 25(12): 1994–1995
103. Sevincok L, Akoglu A, Akyol A (2007) Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 27(1):107–108
104. Hicks CW et al (2011) Valproate for the treatment of medication- induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord 17(5):379–381
105. Bermejo PE (2008) Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 14(5):448–449
106. Bermejo PE, Ruiz-Huete C, Anciones B (2010) Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol 257(10):1682–1685
107. Gerschlager W, Bloem BR (2009) Managing pathological gambling in Parkinson’s disease with enteral levodopa/carbidopa infusions. Mov Disord 24(12):1858–1860
108. Grant JE et al (2006) Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163(2):303–312
109. Kim SW et al (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49(11):914–921
110. Schreiber L, Odlaug BL, Grant JE (2011) Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front Psychiatry 2:1
111. Grant JE, Kim SW, Odlaug BL (2007) N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 62(6):652–657
112. Leroi I et al (2012) Carer burden in apathy and impulse control disorders in Parkinson’s disease. Int J Geriatr Psychiatry 27(2):160–166. doi:10.1002/gps.2704
113. A’Campo LE et al (2012) Treatment effect modifiers for the patient education programme for Parkinson’s disease. Int J Clin Pract 66(1):77–83
114. Roland KP, Jenkins ME, Johnson AM (2010) An exploration of the burden experienced by spousal caregivers of individuals with Parkinson’s disease. Mov Disord 25(2):189–193
115. Brodaty H, Hadzi-Pavlovic D (1990) Psychosocial effects on carers of living with persons with dementia. Aust N Z J Psychiatry 24(3):351–361
116. Schulz R et al (1995) Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 35(6):771–791
117. Clare L et al (2002) Depression and anxiety in memory clinic attenders and their carers: implications for evaluating the effectiveness of cognitive rehabilitation interventions. Int J Geriatr Psychiatry 17(10):962–967
118. Cooper C, Balamurali TB, Livingston G (2007) A systematic review of the prevalence and covariates of anxiety in caregivers of people with dementia. Int Psychogeriatr 19(2):175–195
119. Cooper C et al (2007) A systematic review of intervention studies about anxiety in caregivers of people with dementia. Int J Geriatr Psychiatry 22(3):181–188
120. Cuijpers P (2005) Depressive disorders in caregivers of dementia patients: a systematic review. Aging Ment Health 9(4):325–330
121. Fiore J, Becker J, Coppel DB (1983) Social network interactions: a buffer or a stress. Am J Community Psychol 11(4):423–439
122. Dura JR, Stukenberg KW, Kiecolt-Glaser JK (1990) Chronic stress and depressive disorders in older adults. J Abnorm Psychol 99(3):284–290
123. Carter JH et al (2008) Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression? Mov Disord 23(9):1211–1216
124. O’Reilly F et al (1996) The effects of caring for a spouse with Parkinson’s disease on social, psychological and physical wellbeing. Br J Gen Pract 46(410):507–512
125. Baumgarten M et al (1992) The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol 45(1):61–70
126. Haley WE et al (2004) Well-being, appraisal, and coping in African-American and Caucasian dementia caregivers: findings from the REACH study. Aging Ment Health 8(4):316–329
127. Vedhara K et al (1999) Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. Lancet 353(9153):627–631
128. Lee S et al (2003) Caregiving and risk of coronary heart disease in US women: a prospective study. Am J Prev Med 24(2):113–119
129. Kiecolt-Glaser JK et al (1991) Spousal caregivers of dementia victims: longitudinal changes in immunity and health. Psychosom Med 53(4):345–362
130. Pinquart M, Sorensen S (2003) Differences between caregivers and non caregivers in psychological health and physical health: a meta-analysis. Psychol Aging 18(2):250–267
131. Bauer ME et al (2000) Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids. J Neuroimmunol 103(1):84–92
132. Da Roza Davis JM, Cowen PJ (2001) Biochemical stress of caring. Psychol Med 31:1475–1478. doi:10.1017/S003329170105398z
133. Vitaliano PP, Zhang J, Scanlan JM (2003) Is caregiving hazardous to one’s physical health? A meta-analysis. Psychol Bull 129(6):946–972
134. Wimo A, Jonsson L, Winblad B (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21(3):175–181
135. Cassie KM, Sanders S (2008) Familial caregivers of older adults. J Gerontol Soc Work 50(Suppl 1):293–320
136. Ferri CP et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503):2112–2117
137. Brodaty H, Donkin M (2009) Family caregivers of people with dementia. Dialogues Clin Neurosci 11(2):217–228
138. National Opinion Research Center at the University of Chicago (NORC) (1999) Gambling Impact and Behavior Study: report to the National Gambling Impact Study Commission. Government Printing Office, Washington DC
139. Shaw MC et al (2007) The effect of pathological gambling on families, marriages, and children. CNS Spectr 12(8):615–622
140. Ciarrocchi J, Reinert D (1993) Family environment and length of recovery for married male members of Gamblers Anonymous and female members of GamAnon. J Gambl Stud 9(4):341–352
141. Muelleman RL et al (2002) Problem gambling in the partner of the emergency department patient as a risk factor for intimate partner violence. J Emerg Med 23(3):307–312
142. Jacobs DF et al (1989) Children of problem gamblers. J Gambl Behav 5(4):261–268
143. Weintraub D, Potenza MN (2006) Impulse control disorders in Parkinson’s disease. Curr Neurol Neurosci Rep 6(4):302–306